Combination treatment with a selective androgen receptor modulator (SARM) and a bisphosphonate has additive effects in osteopenic female rats

Journal of Bone and Mineral Research

Volumn 24, Issue 2, 2009, Pages 231-240

  Vajda, Eric G ^a   Hogue, Aimee ^a   Griffiths, Kimberly N ^a   Chang, William Y ^a   Burnett, Kelven ^a   Chen, Yanling ^a   Marschke, Keith ^a   Mais, Dale E ^a   Pedram, Bijan ^a   Shen, Yixing ^a   Van Oeveren, Arjan ^a   Zhi, Lin ^a   López, Francisco J ^a   Meglasson, Martin D ^a  

^a LIGAND PHARMACEUTICALS INC   (United States)

Author keywords

Androgens; Animal models; Bisphosphonates; Muscle; Osteoporosis; Selective androgen receptor modulator

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CELL NUCLEUS RECEPTOR; LGD 3303; OSTEOCALCIN; SELECTIVE ANDROGEN RECEPTOR MODULATOR; TESTOSTERONE PROPIONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; CANCELLOUS BONE; CONTROLLED STUDY; CORTICAL BONE; CROSS REACTION; DRUG POTENCY; DRUG POTENTIATION; DRUG SELECTIVITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; LEVATOR ANI MUSCLE; MALE; MORPHOMETRICS; MUSCLE MASS; NONHUMAN; ORCHIECTOMY; OSTEOPENIA; OSTEOPOROSIS; OVARIECTOMY; PERIOSTEUM; RAT;

ABSORPTIOMETRY, PHOTON; ANDROGEN ANTAGONISTS; ANIMALS; BIOMECHANICS; BODY WEIGHT; BONE DENSITY; BONE DISEASES, METABOLIC; DIPHOSPHONATES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; ESTROGENS; FEMALE; FEMUR; LUMBAR VERTEBRAE; MALE; ORCHIECTOMY; ORGAN SIZE; OSTEOCALCIN; OVARIECTOMY; PYRROLES; QUINOLONES; RATS; RATS, SPRAGUE-DAWLEY; TRANSCRIPTION, GENETIC;

EID: 58649104171     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.081007     Document Type: Article

References (32)

1. Russell RG 2006 Bisphosphonates: From bench to bedside. Ann NY Acad Sci 1068:367-401.
2. Kavanagh KL, Guo K, Dunford JE, Wu X, Knapp S, Ebetino FH, Rogers MJ, Russell RG, Oppermann U 2006 The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs. Proc Natl Acad Sci USA 103:7829-7834.
3. Azuma Y, Oue Y, Kanatani H, Ohta T, Kiyoki M, Komoriya K 1998 Effects of continuous alendronate treatment on bone mass and mechanical properties in ovariectomized rats: Comparison with Pamidronate and etidronate in growing rats. J Pharmacol Exp Ther 286:128-135.
4. Allen MR, Follet H, Khurana M, Sato M, Burr DB 2006 Antiremodeling agents influence osteoblast activity differently in modeling and remodeling sites of canine rib. Calcif Tissue Int 79:255-261.
5. Coxam V, Bowman BM, Mecham M, Roth CM, Miller MA, Miller SC 1996 Effects of dihydrotestosterone alone and combined with estrogen on bone mineral density, bone growth, and formation rates in ovariectomized rats. Bone 19:107-114.
6. Tobias JH, Gallagher A, Chambers TJ 1994 5 alpha-Dihydrotestosterone partially restores cancellous bone volume in osteopenic ovariectomized rats. Am J Physiol 267:E853-E859.
7. Chesnut CH, III, Ivey JL, Gruber HE, Matthews M, Nelp WB, Sisom K, Baylink DJ 1983 Stanozolol in postmenopausal osteoporosis: Therapeutic efficacy and possible mechanisms of action. Metabolism 32:571-580.
8. Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD 1997 Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis. Osteoporos Int 7:29-35.
9. Passeri M, Pedrazzoni M, Pioli G, Butturini L, Ruys AH, Cortenraad MG 1993 Effects of nandrolone decanoate on bone mass in established osteoporosis. Maturitas 17:211-219.
10. Barrett-Connor E, Young R, Notelovitz M, Sullivan J, Wiita B, Yang HM, Nolan J 1999 A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. J Reprod Med 44:1012-1020.
11. Ostrowski J, Kuhns JE, Lupisella JA, Manfredi MC, Beehler BC, Krystek SR Jr, Bi Y, Sun C, Seethala R, Golla R, Sleph PG, Fura A, An Y, Kish KF, Sack JS, Mookhtiar KA, Grover GJ, Hamann LG 2007 Pharmacological and x-ray structural characterization of a novel selective androgen receptor modulator: Potent hyperanabolic stimulation of skeletal muscle with hypostimulation of prostate in rats. Endocrinology 148:4-12.
12. Hanada K, Furuya K, Yamamoto N, Nejishima H, Ichikawa K, Nakamura T, Miyakawa M, Amano S, Sumita Y, Oguro N 2003 Bone anabolic effects of S-40503, a novel nonsteroidal selective androgen receptor modulator (SARM), in rat models of osteoporosis. Biol Pharm Bull 26:1563-1569.
13. Gao W, Kearbey JD, Nair VA, Chung K, Parlow AF, Miller DD, Dalton JT 2004 Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: New approach for benign prostate hyperplasia. Endocrinology 145:5420-5428.
14. Miner JN, Chang W, Chapman MS, Finn PD, Hong MH, Lopez FJ, Marschke KB, Rosen J, Schrader W, Turner R, van Oeveren A, Viveros H, Zhi L, Negro-Vilar A 2007 An orally active selective androgen receptor modulator is efficacious on bone, muscle, and sex function with reduced impact on prostate. Endocrinology 148:363-373.
15. Kearbey JD, Gao W, Narayanan R, Fisher SJ, Wu D, Miller DD, Dalton JT 2007 Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharm Res 24:328-335.
16. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ 2003 The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207-1215.
17. Pedram B, van Oeveren A, Zhi L, Zhao S, Shen Y 2006 Androgen receptor modulator compounds and methods. Patent WO 138347.
18. Gee AC, Carlson KE, Martini PG, Katzenellenbogen BS, Katzenellenbogen JA 1999 Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor. Mol Endocrinol 13:1912-1923.
19. Waynforth HB, Flecknell PA 1992 Experimental and Surgical Technique in the Rat. Academic Press, London, UK.
20. Vajda EG, Bowman BM, Miller SC 2001 Cancellous and cortical bone mechanical properties and tissue dynamics during pregnancy, lactation, and postlactation in the rat. Biol Reprod 65:689-695.
21. Turner CH, Burr DB, 1993 Basic biomechanical measurements of bone: A tutorial. Bone 14:595-608.
22. Recker RR 1983 Bone Histomorphometry: Techniques and Interpretation. CRC Press, Baco Raton, FL, USA.
23. Turner RT, Evans GL, Wakley GK 1993 Mechanism of action of estrogen on cancellous bone balance in tibiae of ovariectomized growing rats: Inhibition of indices of formation and resorption. J Bone Miner Res 8:359-366.
24. Cavolina JM, Evans GL, Harris SA, Zhang M, Westerlind KC, Turner RT 1997 The effects of orbital spaceflight on bone histomorphometry and messenger ribonucleic acid levels for bone matrix proteins and skeletal signaling peptides in ovariectomized growing rats. Endocrinology 138:1567-1576.
25. Mosekilde L, Thomsen JS, Mackey MS, Phipps RJ 2000 Treatment with risedronate or alendronate prevents hind-limb immobilization-induced loss of bone density and strength in adult female rats. Bone 27:639-645.
26. Balena R, Markatos A, Seedor JG, Gentile M, Stark C, Peter CP, Rodan GA 1996 Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae. J Pharmacol Exp Ther 276:277-283.
27. Peter C, Rodan GA, 1999 Preclinical safety profile of alendronate. Int J Clin Pract Suppl 101:3-8.
28. Bourrin S, Ammann P, Bonjour JP, Rizzoli R 2002 Recovery of proximal tibia bone mineral density and strength, but not cancellous bone architecture, after long-term bisphosphonate or selective estrogen receptor modulator therapy in aged rats. Bone 30:195-200.
29. Brouwers JE, Lambers FM, Gasser JA, van Rietbergen B, Huiskes R 2008 Bone degeneration and recovery after early and late bisphosphonate treatment of ovariectomized wistar rats assessed by in vivo micro-computed tomography. Calcif Tissue Int 82:202-211.
30. Kippo K, Hannuniemi R, Lauren L, Peng Z, Kuurtamo P, Virtamo T, Isaksson P, Osterman T, Vaananen HK, Sellman R 1998 Effect of clodronate treatment on established bone loss in ovariectomized rats. Bone 23:333-342.
31. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H, Yeh JK 2006 Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats. J Nutr Sci Vitaminol (Tokyo) 52:1-8.
32. DeManno D, Miller S, Vajda E, Gunawardhana L, Niehoff M, Weinbauer GF 2006 LGD2941, an orally-available, non-steroidal, selective androgen receptor modulator (SARM) stimulates bone and muscle growth in male monkeys. J Bone Miner Res 21: S1;M389.